Oculis Completes Randomization of 176 Patients in Dry Eye Trial
Oculis completed randomization in its PREDICT-1 registrational trial of licaminlimab for TNFR1-mediated dry eye disease. Topline data are expected around year-end 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results.
Oculis Completes Randomization in Licaminlimab PREDICT-1 Trial
Oculis said randomization is complete in its registrational trial of licaminlimab for TNFR1-mediated dry eye disease. Two-thirds of the 176 enrolled patients carry the TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials.
Oculis Completes Randomization in Licaminlimab PREDICT-1 Trial
Oculis says 176 patients were enrolled, with two-thirds carrying a TNFR1 genetic variant linked to increased clinical response in phase 2 studies.
Oculis Completes Randomization in Licaminlimab Registrational Trial
Oculis said randomization is complete in the PREDICT-1 registrational trial of licaminlimab for TNFR1-mediated dry eye disease.